@article{2997727,
    title = "Response to correspondence: Testing for myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in typical MS",
    author = "Breza, M. and Koutsis, G. and Tzartos, J.S. and Velonakis, G. and Evangelopoulos, M.E. and Tzanetakos, D. and Karagiorgou, K. and Angelopoulou, G. and Kasselimis, D. and Potagas, C. and Anagnostouli, M. and Stefanis, L. and Kilidireas, C.",
    journal = "Multiple Sclerosis and Related Disorders",
    year = "2019",
    volume = "35",
    pages = "156-157",
    publisher = "Elsevier B.V.",
    issn = "2211-0348",
    doi = "10.1016/j.msard.2019.07.018",
    keywords = "biological marker;  complement;  immunoglobulin G;  immunoglobulin G1 antibody;  myelin oligodendrocyte glycoprotein antibody;  protein antibody;  unclassified drug;  immunoglobulin G;  myelin oligodendrocyte glycoprotein, antibody titer;  antigen specificity;  brain damage;  cell assay;  clinical feature;  conus medullaris;  corpus callosum;  demyelinating disease;  disease association;  false positive result;  human;  immunoassay;  Letter;  multiple sclerosis;  nuclear magnetic resonance imaging;  patient care;  phenotype;  prognosis;  demyelinating disease, Demyelinating Diseases;  Humans;  Immunoglobulin G;  Multiple Sclerosis;  Myelin-Oligodendrocyte Glycoprotein"
}